These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 25144265

  • 1. The Efficacy of Palonosetron Plus Dexamethasone in Preventing Chemoradiotherapy-induced Nausea and Emesis in Patients Receiving Daily Low-dose Cisplatin-based Concurrent Chemoradiotherapy for Uterine Cervical Cancer: A Phase II Study.
    Mitsuhashi A, Usui H, Nishikimi K, Yamamoto N, Hanawa S, Tate S, Watanabe-Nemoto M, Uno T, Shozu M.
    Am J Clin Oncol; 2017 Apr; 40(2):118-121. PubMed ID: 25144265
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of palonosetron plus aprepitant in preventing chemoradiotherapy-induced nausea and emesis in patients receiving daily low-dose cisplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a phase II study.
    Hanawa S, Mitsuhashi A, Matsuoka A, Nishikimi K, Tate S, Usui H, Uno T, Shozu M.
    Support Care Cancer; 2016 Nov; 24(11):4633-8. PubMed ID: 27286875
    [Abstract] [Full Text] [Related]

  • 3. Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin-a phase II study.
    Ruhlmann CH, Belli C, Dahl T, Herrstedt J.
    Support Care Cancer; 2013 Dec; 21(12):3425-31. PubMed ID: 23949739
    [Abstract] [Full Text] [Related]

  • 4. A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin.
    Maeda A, Ura T, Asano C, Haegawa I, Nomura M, Komori A, Narita Y, Taniguchi H, Kadowaki S, Muro K, Horio Y, Yoshida T, Oze I, Kajita M, Mizutani A.
    Asia Pac J Clin Oncol; 2016 Sep; 12(3):254-8. PubMed ID: 27030364
    [Abstract] [Full Text] [Related]

  • 5. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY.
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [Abstract] [Full Text] [Related]

  • 6. Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
    Roila F, Ruggeri B, Ballatori E, Fatigoni S, Caserta C, Licitra L, Mirabile A, Ionta MT, Massidda B, Cavanna L, Palladino MA, Tocci A, Fava S, Colantonio I, Angelelli L, Ciuffreda L, Fasola G, Zerilli F.
    Ann Oncol; 2015 Jun; 26(6):1248-1253. PubMed ID: 25743855
    [Abstract] [Full Text] [Related]

  • 7. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
    Miura S, Watanabe S, Sato K, Makino M, Kobayashi O, Miyao H, Iwashima A, Okajima M, Tanaka J, Tanaka H, Kagamu H, Yokoyama A, Narita I, Yoshizawa H.
    Support Care Cancer; 2013 Sep; 21(9):2575-81. PubMed ID: 23644992
    [Abstract] [Full Text] [Related]

  • 8. Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy.
    Yang CK, Wu CE, Liaw CC.
    Biomed J; 2016 Feb; 39(1):60-6. PubMed ID: 27105599
    [Abstract] [Full Text] [Related]

  • 9. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.
    Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT, Bubalo J.
    Support Care Cancer; 2007 Nov; 15(11):1293-1300. PubMed ID: 17436025
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
    Ruhlmann CH, Christensen TB, Dohn LH, Paludan M, Rønnengart E, Halekoh U, Hilpert F, Feyer P, Kristensen G, Hansen O, Keefe D, Herrstedt J.
    Lancet Oncol; 2016 Apr; 17(4):509-518. PubMed ID: 26952945
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
    Abe M, Hirashima Y, Kasamatsu Y, Kado N, Komeda S, Kuji S, Tanaka A, Takahashi N, Takekuma M, Hihara H, Ichikawa Y, Itonaga Y, Hirakawa T, Nasu K, Miyagi K, Murakami J, Ito K.
    Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
    Kusagaya H, Inui N, Karayama M, Fujisawa T, Enomoto N, Kuroishi S, Nakamura Y, Matsuda H, Yokomura K, Koshimizu N, Toyoshima M, Imokawa S, Yamada T, Shirai T, Hayakawa H, Suda T.
    Lung Cancer; 2015 Dec; 90(3):410-6. PubMed ID: 26791800
    [Abstract] [Full Text] [Related]

  • 13. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Longo F, Mansueto G, Lapadula V, De Sanctis R, Quadrini S, Grande R, Gori B, Altavilla A, D'Antoni I, Del Signore E, Stumbo L, De Luca C, Cimadon B, Cortesi E, Gamucci T, Di Seri M.
    Support Care Cancer; 2011 Aug; 19(8):1159-64. PubMed ID: 20552375
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H, Yamamoto N, Shirai T, Nishida H, Hayashi K, Tanzawa Y, Takeuchi A, Igarashi K, Inatani H, Shimozaki S, Kato T, Aoki Y, Higuchi T, Tsuchiya H.
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [Abstract] [Full Text] [Related]

  • 15. A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy.
    Maemondo M, Masuda N, Sekine I, Kubota K, Segawa Y, Shibuya M, Imamura F, Katakami N, Hida T, Takeo S, PALO Japanese Cooperative Study Group.
    Ann Oncol; 2009 Nov; 20(11):1860-6. PubMed ID: 19561037
    [Abstract] [Full Text] [Related]

  • 16. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA.
    J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Oyama K, Fushida S, Kaji M, Takeda T, Yabushita K, Nezuka H, Kinami S, Kadoya N, Takai Y, Tsukioka Y, Ohyama S, Tsuji K, Tsukada T, Kinoshita J, Fujimura T, Ohta T.
    Int J Clin Oncol; 2016 Jun; 21(3):483-90. PubMed ID: 26507140
    [Abstract] [Full Text] [Related]

  • 18. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S.
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [Abstract] [Full Text] [Related]

  • 19. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
    Nakashima K, Murakami H, Yokoyama K, Omori S, Wakuda K, Ono A, Kenmotsu H, Naito T, Nishiyama F, Kikugawa M, Kaneko M, Iwamoto Y, Koizumi S, Mori K, Isobe T, Takahashi T.
    Jpn J Clin Oncol; 2017 Sep 01; 47(9):840-843. PubMed ID: 28633504
    [Abstract] [Full Text] [Related]

  • 20. Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin.
    Jahn F, Riesner A, Jahn P, Sieker F, Vordermark D, Jordan K.
    Int J Radiat Oncol Biol Phys; 2015 Aug 01; 92(5):1101-1107. PubMed ID: 26059352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.